Savara Inc P/S Ratio
The price-to-sales (P/S) ratio tells you how many dollars investors pay for each dollar of a company's annual revenue. It is market capitalization divided by revenue over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/S means investors are paying more for each dollar of sales; because revenue is rarely negative, the ratio stays usable for companies that are not yet profitable. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Savara Inc p/s ratio for the quarter ending 2020-12-31 was 242.32.
- Savara Inc p/s ratio for the quarter ending 2020-09-30 was 230.51.
- Savara Inc p/s ratio for fiscal 2020 was 242.32.
- Available history
- 2020-09-30 to 2020-12-31
- Data captured
Historical P/S Ratio
Annual P/S Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |